Start the program by clicking on the Start Program icon at the bottom of this page.
|
| Program Title |
 |
|
Antiangiogenic Therapies for Malignant Gliomas
Release Date: July-28-09
Credit Expiration Date: July-28-10
|
|
|
 |
| Program Developer/Facilitator |
 |
|
Medical Communications Media, Inc. |
|
|
|
| Target Audience |
|
|
| This educational activity is designed to meet the needs of neurosurgeons, neuro-oncologists, radiation oncologists, medical oncologists, and other healthcare providers interested in the treatment of primary gliomas. |
|
|
|
| Credit Hours |
|
|
|
|
|
| Medium |
|
|
|
|
|
| Program Description |
|
|
| As a result of the ongoing effort to develop more effective treatments for malignant gliomas, translational research has exposed many of the genetic and molecular secrets of these tumors. Targeted therapies are under development to treat the unique vasculature of glioblastomas. Studies are showing that angiogenics may be vital for tumor survival; therefore, the recent successes in preclinical and clinical testing of antiangiogenics offers hope to those suffering from more aggressive forms of glioma. This program discusses the benefits and risks of these targeted therapies and offers thoughts about the future of these treatments. |
|
|
|
| Learning Objectives |
|
|
|
|
|
| Faculty |
|
|
Disha Patel
Research Associate
Ohio State University Medical School
Arthur G. James Comprehensive Cancer Center and
Richard L. Solove Research Institute
Columbus, OH
Arnab Chakravarti, MD
Chair & Professor, Department of Radiation Oncology
Ohio State University Medical School
Co-Director, Brain Tumor Program
Arthur G. James Comprehensive Cancer Center and
Richard L. Solove Research Institute
Columbus, OH
|
|
|
|
| Disclosures |
|
|
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Ms. Patel has no relevant financial conflicts to disclose.
Dr. Chakravarti discloses that he serves on the speakers’ bureau of Schering-Plough and is a consultant for Genentech.
|
|
|
|
| Commercial Support Statements |
|
|
This activity is supported by an educational grant from Schering-Plough. |
|
|
|
|
|
| Credit Statements |
|
|
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Incorporated. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians. |
|
|
AKH Inc. designates this educational activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
|
|
|
|
|
| Instructions |
|
|
|
|
|
| Certificate Fee |
|
|
|
|
|
| Disclaimer |
|
|
| © 2009. All rights reserved. None of the contents of this publication may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this publication are those of the faculty members and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or Schering-Plough. Any medications, diagnostic procedures, or treatments discussed by the faculty members should not be used by clinicians or other healthcare professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities. |
|
|
| |
